HOME > NEWS
News
09/09/2009
iCardiac's COMPAS Analytics Used in Recent New Drug Approval
Rochester, NY -- iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development and automated QT analysis, announced that its full suite of advanced cardiac safety methods including Highly Automated QT, Dynamic QT beat-to-beat as well as BeyondQT have been used in an FDA submission to support a new drug approval.
"We are enthusiastic about our continued progress in supporting drug approvals for our pharmaceutical and biotechnology clients," said Sasha Latypova, Executive Vice President. "What is especially exciting about this program is that iCardiac's methods were able to provide key scientific evidence indicating that the drug does not appear to have arrhythmia liability despite QT prolongation. The drug has now been approved by the FDA with a clean cardiac safety label."
In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision, high rate of false positives/negatives, and high cost of the "gold standard" manual or semi-automated QT measurements has lead to efforts toward providing more advanced cardiac safety analytics.
About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including Highly Automated QT, which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies.
About Stonehenge Growth Capital
Stonehenge Growth Capital (“Stonehenge”) (www.stonehengegc.com) manages over $677 million in venture capital, private equity and mezzanine debt funds for Stonehenge Capital Company ("SCC"). SCC is a nationwide specialty finance firm with expertise in principal investment, asset management, tax credit finance and structured finance transactions. In addition to Stonehenge’s principal investment activities, SCC has closed more than $1 billion of structured finance and tax credit transactions from its offices in Alabama, Colorado, Florida, Louisiana, Missouri, New York, Ohio, Texas and Wisconsin.
"We are enthusiastic about our continued progress in supporting drug approvals for our pharmaceutical and biotechnology clients," said Sasha Latypova, Executive Vice President. "What is especially exciting about this program is that iCardiac's methods were able to provide key scientific evidence indicating that the drug does not appear to have arrhythmia liability despite QT prolongation. The drug has now been approved by the FDA with a clean cardiac safety label."
In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision, high rate of false positives/negatives, and high cost of the "gold standard" manual or semi-automated QT measurements has lead to efforts toward providing more advanced cardiac safety analytics.
About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including Highly Automated QT, which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies.
About Stonehenge Growth Capital
Stonehenge Growth Capital (“Stonehenge”) (www.stonehengegc.com) manages over $677 million in venture capital, private equity and mezzanine debt funds for Stonehenge Capital Company ("SCC"). SCC is a nationwide specialty finance firm with expertise in principal investment, asset management, tax credit finance and structured finance transactions. In addition to Stonehenge’s principal investment activities, SCC has closed more than $1 billion of structured finance and tax credit transactions from its offices in Alabama, Colorado, Florida, Louisiana, Missouri, New York, Ohio, Texas and Wisconsin.
| Associated Company |
| iCardiac Technologies, Inc. |
| Associated Office |
| New York |
